Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, a HER2/neu transmembrane peptide currently in a Phase III clinical trial aimed at preventing breast cancer recurrences in patients. The company also develops FLAMINGO-01, a program that includes a Phase IIb and three Phase I clinical trials designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences operates exclusively in the United States and is dedicated to advancing immunotherapeutic treatments for cancer.

Greenwich LifeSciences, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol GLSI. The company's shares are traded in United States Dollars (USD), reflecting its primary listing in the U.S. equity market. As a Nasdaq-listed company, it is subject to the exchange's listing standards and regulatory requirements, providing investors with a transparent and regulated trading environment. The use of USD as the trading currency aligns with the company's operations and headquarters in the United States.

Greenwich LifeSciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies, particularly immunotherapies for cancer. The biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight. Greenwich LifeSciences' work in developing cancer immunotherapies places it at the forefront of precision medicine, targeting specific biomarkers like HER2/neu to create treatments that harness the body's immune system to fight cancer.

Greenwich LifeSciences, Inc. is headquartered in Stafford, Texas, United States. The company was originally incorporated in 2006 under the name Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. This name change reflected the company's strategic shift toward developing cancer immunotherapies. As a clinical-stage biopharmaceutical company, it operates primarily in the U.S. market, focusing on advancing its lead product candidate GP2 and other pipeline assets for HER2/neu-expressing cancers. The company's location in Texas places it within a growing biotechnology hub.

Greenwich LifeSciences' primary product candidate is GP2, a HER2/neu transmembrane peptide immunotherapy currently in Phase III clinical trials for preventing breast cancer recurrences. Additionally, the company is developing FLAMINGO-01, which encompasses a Phase IIb and three Phase I clinical trials evaluating GLSI-100 in HER2 positive breast cancer patients. GLSI-100 is designed to stimulate the immune system to target cancer cells expressing HER2/neu. These candidates represent the company's focus on immunotherapies that aim to reduce the risk of cancer recurrence and improve outcomes for patients with HER2/neu-expressing cancers.